See What HealthDay Can Do For You
Contact Us

Humanized Protein May Allow Anti-Thrombotic Screening

Protein affects hemostasis and thrombosis by binding to platelet receptors

MONDAY, Jan. 7 (HealthDay News) -- Modifying the mouse version of a protein that affects hemostasis and thrombosis by binding to platelet receptors allows the protein to bind human platelet receptors and may be a platform to screen anti-thrombotic drugs, according to the results of a study published online Dec. 16 in Nature Biotechnology.

Jianchun Chen, from Columbia University Medical Center in New York City, and colleagues modified an electrostatic "hot-spot" in the mouse version of the A1 domain of von Willebrand factor (VWF-A1) to improve its binding to the human platelet receptor glycoprotein Ib alpha (GPIbα).

The researchers found that the binding specificity of the modified VWF-A1 changed from the mouse to human GPIbα. Mice engineered to produce the modified VWF-A1 had a bleeding phenotype that was corrected by an infusion of human platelets, which formed occlusive thrombi.

"Thus, by modifying a protein interface, we have generated a potential biological platform for pre-clinical screening of anti-thrombotics that specifically target human platelets," Chen and colleagues conclude.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.